Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anatomy Of A Patent Dispute: Purdue Pharma’s OxyContin Battle

Executive Summary

Two years ago, Purdue Pharma's lawyers anxiously gathered together on a conference call. The U.S. Court of Appeals for the Federal Circuit had just issued its second opinion in OxyContin patent litigation. But the court's earlier ruling had accidentally been posted online. For a tense 20 minutes they waited until one of Purdue's outside attorneys got the final decision

You may also be interested in...



Patent Expiration May Not Help OxyContin Generics

OxyContin’s method of treatment patent expires April 16, but several patents remain tied up in litigation over APIs as Purdue and generic companies await FDA decision on whether the original formulation can be a reference product.

At-Risk Launches: Three Cases May Determine How Damages Are Calculated

How risky are at-risk launches of generic products?

At-Risk Launches: Three Cases May Determine How Damages Are Calculated

How risky are at-risk launches of generic products?

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS049373

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel